{"id":297540,"date":"2016-10-18T11:00:00","date_gmt":"2016-10-18T11:00:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=3388ab4a3748e1faf344e41923c831a0"},"modified":"2016-10-18T11:00:00","modified_gmt":"2016-10-18T11:00:00","slug":"sunesis-pharmaceuticals-to-present-at-the-dawson-james-securities-2nd-annual-small-cap-growth-stock-conference","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/sunesis-pharmaceuticals-to-present-at-the-dawson-james-securities-2nd-annual-small-cap-growth-stock-conference\/","title":{"rendered":"Sunesis Pharmaceuticals to Present at the Dawson James Securities 2nd Annual Small Cap Growth Stock Conference"},"content":{"rendered":"<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Oct.  18, 2016  (GLOBE NEWSWIRE) &#8212; Sunesis Pharmaceuticals, Inc. (Nasdaq:<a href=\"http:\/\/globenewswire.com\/News\/Listing?symbol=SNSS&#038;exchange=2\">SNSS<\/a>) today announced that Eric Bjerkholt, Chief Financial Officer of Sunesis, will present at the Dawson James Securities 2<sup>nd<\/sup> Annual Small Cap Growth Stock Conference on Thursday, October 20<sup>th<\/sup> at 9:30 AM Eastern Time at the Wyndham Grand Hotel in Jupiter, Florida.<\/p>\n<p align=\"justify\">A live webcast of the presentation will be available on the Sunesis website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QnO6va8re3utMHw2VrDde8-HNnnsx41J8Pp7rdPdQcBU5TBSaQGm1TbrCTW_WXRn_-sKfx0XPIA4XWUtTzrktA==\" rel=\"nofollow\"  title=\"\">http:\/\/ir.sunesis.com<\/a>.<\/p>\n<p align=\"justify\">A replay of the webcast will be archived on the &#8220;Calendar of Events&#8221; page in the Investors and Media section of the Sunesis website for two weeks.<\/p>\n<p align=\"justify\"><strong>About Sunesis Pharmaceuticals<\/strong><br \/>Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer. Currently, the company is focused on pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older, as well as advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor, SNS-062.<\/p>\n<p>For additional information on Sunesis, please visit&#160;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QnO6va8re3utMHw2VrDdeztCZN3nH7jF8WkQKCwgcIMJTHRhaa_CaiypvU3GK75OPoZ6yGexwV2JWdk3ut9fJGWmPcVeAkOr1AFYO-6aQQs=\" rel=\"nofollow\"  title=\"\">http:\/\/www.sunesis.com<\/a>.<\/p>\n<p align=\"justify\">SUNESIS and the logos are trademarks of&#160;Sunesis Pharmaceuticals, Inc.<\/p>\n<p>&#160;<\/p>\n<pre>CONTACT: Investor and Media Inquiries:\nDavid Pitts\nArgot Partners\n212-600-1902 \n\nEric Bjerkholt\nSunesis Pharmaceuticals Inc.\n650-266-3717<\/pre>\n","protected":false},"excerpt":{"rendered":"<p class=\"small\" align=\"left\">SOUTH SAN FRANCISCO, Calif., Oct.  18, 2016  (GLOBE NEWSWIRE) &#8212; Sunesis Pharmaceuticals, Inc. (Nasdaq:<a href=\"http:\/\/globenewswire.com\/News\/Listing?symbol=SNSS&amp;exchange=2\">SNSS<\/a>) today announced that Eric Bjerkholt, Chief Financial Officer of Sunesis, will present at the Dawson James Securities 2<sup>nd<\/sup> Annual Small Cap Growth Stock Conference on Thursday, October 20<sup>th<\/sup> at 9:30 AM Eastern Time at the Wyndham Grand Hotel in Jupiter, Florida.<\/p>\n<p class=\"small\" align=\"justify\">A live webcast of the presentation will be available on the Sunesis website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QnO6va8re3utMHw2VrDde8-HNnnsx41J8Pp7rdPdQcBU5TBSaQGm1TbrCTW_WXRn_-sKfx0XPIA4XWUtTzrktA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">http:\/\/ir.sunesis.com<\/a>.<\/p>\n<p class=\"small\" align=\"justify\">A replay of the webcast will be archived on the &#8220;Calendar of Events&#8221; page in the Investors and Media section of the Sunesis website for two weeks.<\/p>\n<p class=\"small\" align=\"justify\"><strong>About Sunesis Pharmaceuticals<\/strong><br \/>Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer. Currently, the company is focused on pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older, as well as advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor, SNS-062.<\/p>\n<p class=\"small\">For additional information on Sunesis, please visit&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QnO6va8re3utMHw2VrDdeztCZN3nH7jF8WkQKCwgcIMJTHRhaa_CaiypvU3GK75OPoZ6yGexwV2JWdk3ut9fJGWmPcVeAkOr1AFYO-6aQQs=\" rel=\"nofollow\" target=\"_blank\" title=\"\">http:\/\/www.sunesis.com<\/a>.<\/p>\n<p class=\"small\" align=\"justify\">SUNESIS and the logos are trademarks of&nbsp;Sunesis Pharmaceuticals, Inc.<\/p>\n<p class=\"small\">&nbsp;<\/p>\n<p class=\"small\"re>CONTACT: Investor and Media Inquiries:\nDavid Pitts\nArgot Partners\n212-600-1902 \n\nEric Bjerkholt\nSunesis Pharmaceuticals Inc.\n650-266-3717<\/pre>\n","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71360],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/297540"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=297540"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/297540\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=297540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=297540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=297540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}